Stomach cancer treatment in Turkey should begin with confirmation of the diagnosis, stage and treatment intent—not with the choice of a hospital, operation or medicine. The appropriate plan depends on the exact tumour type, its location within the stomach, whether it can be removed completely, the patient’s nutritional and general condition, previous treatment and relevant biomarker results.
This guide mainly discusses gastric adenocarcinoma, the most common form of stomach cancer. Lymphoma, gastrointestinal stromal tumour, neuroendocrine tumour and other uncommon cancers that arise in the stomach follow different pathways. Tumours at the gastro-oesophageal junction may also require an oesophagogastric treatment approach rather than the same plan used for a cancer arising lower in the stomach.
The purpose of this article is to explain how specialists stage stomach cancer and how endoscopic treatment, surgery, chemotherapy, immunotherapy, targeted therapy, radiotherapy, nutrition and supportive care may fit into an individual plan. It also explains which records international patients should send before travelling and how treatment can be coordinated after returning home. Final decisions must be made by licensed clinicians who have reviewed the complete case.
A responsible treatment plan starts with several linked questions. What does the pathology show? Where is the tumour located? How deeply has it grown? Are regional lymph nodes involved? Is there cancer on the peritoneal surface or in distant organs? Can the tumour be removed with clear margins? Is the patient medically and nutritionally fit for the proposed treatment? Could a biomarker change the systemic-therapy choice?
These questions cannot be answered reliably from a short diagnosis, a photograph of one report or an advertised treatment package. The team may need the endoscopy report and images, biopsy material, original radiology studies in DICOM format, operative records, treatment history, current laboratory results and details about weight loss, food intake and symptoms.
The specialists involved can include a gastroenterologist or therapeutic endoscopist, upper gastrointestinal surgeon, medical oncologist, radiation oncologist, gastrointestinal pathologist, diagnostic radiologist, nuclear-medicine physician, molecular-diagnostics team, dietitian, anaesthesiologist and supportive-care team. Complex cases are often discussed at a multidisciplinary tumour board.
A remote review can identify missing information, select the most relevant specialist and outline reasonable next steps before travel. However, a records review may remain preliminary if current examination, pathology review, staging imaging, diagnostic laparoscopy or another biopsy is still required. A written proposal should state which conclusions are supported by the available evidence and which remain conditional.
Most stomach cancers are adenocarcinomas arising from the glandular lining of the stomach. Even within this group, intestinal-type, diffuse-type and signet-ring features can affect behaviour, pathology interpretation, hereditary-risk assessment and surgical planning.
Treatment is not determined by the word “adenocarcinoma” alone. The clinical stage, tumour location, resectability, lymph-node involvement, peritoneal assessment, biomarker profile and patient fitness all matter.
A tumour near the point where the oesophagus meets the stomach may be classified and treated within an oesophagogastric pathway. The operation, lymph-node fields, role of radiotherapy and systemic-treatment sequence can differ from those used for a distal gastric cancer.
International patients should send the full endoscopy and pathology information rather than describing every upper-abdominal cancer simply as “stomach cancer.” Precise localisation helps the reviewing team select the correct surgeon and treatment protocol.
Not every malignant tumour in the stomach is an adenocarcinoma. Gastric lymphoma, gastrointestinal stromal tumour, neuroendocrine neoplasm and metastatic disease involving the stomach require different pathology tests, medicines and surgical strategies.
Applying an adenocarcinoma protocol to one of these diagnoses can lead to inappropriate treatment. When the pathology is rare, uncertain or based on a small sample, specialist review of the original slides or paraffin block may be important before a definitive plan is issued.
Upper gastrointestinal endoscopy allows the doctor to inspect the oesophagus, stomach and first part of the small intestine, record the tumour’s location and appearance and obtain tissue. Several representative biopsies may be required because a single superficial fragment may not show the full tumour or provide enough material for biomarker testing.
The endoscopy report should describe the lesion’s position, size and relationship to anatomical landmarks. Photographs or video can add useful information. If the tumour narrows the passage, causes bleeding or prevents adequate examination, the report should document these limitations.
The pathology report should confirm malignancy and identify the tumour type. For adenocarcinoma, the pathologist may describe differentiation, Lauren classification, diffuse or intestinal features, signet-ring cells and other findings that influence multidisciplinary interpretation.
A written report is important but may not be enough when terminology is unclear, reports conflict or the proposed treatment depends on a precise classification. In these circumstances, a gastrointestinal pathologist may need the original glass slides, paraffin blocks or validated digital-pathology material.
A review or repeat biopsy may be considered when:
Repeat sampling is not automatic. The team should first confirm what material already exists and whether the new procedure could reasonably change management.
Most stomach cancers are not caused by a single inherited syndrome. Genetic counselling may nevertheless be appropriate for selected patients, particularly those diagnosed at a young age, those with diffuse or signet-ring gastric cancer, and families with a pattern of gastric cancer or related cancers.
Specialist assessment may consider genes such as CDH1 or CTNNA1 when the personal and family history is suggestive. A commercial genetic panel should not be ordered without considering how the result will be interpreted and whether it could affect the patient or relatives.
Contrast-enhanced CT of the chest, abdomen and pelvis is commonly used to assess the stomach, regional lymph nodes, liver, lungs and other possible sites of disease. The reviewing radiologist should have access to the original DICOM files, not only a written report or screenshots.
Endoscopic ultrasound can help assess how deeply a tumour extends through the stomach wall and examine nearby lymph nodes, particularly when the result could change endoscopic or surgical planning. It is not necessary in every case and may be less informative when a lesion is obstructing or has already been clearly shown to be advanced.
PET-CT can be useful in selected situations, but it is not required for every patient with stomach cancer. Some gastric tumours show limited tracer uptake, and small peritoneal deposits may remain difficult to detect. MRI or other focused imaging may be requested when CT findings require clarification.
Stomach cancer can spread to the peritoneal lining of the abdomen in deposits too small to be seen reliably on CT or PET-CT. For apparently resectable disease in which perioperative therapy and curative-intent surgery are being considered, diagnostic laparoscopy may be recommended to inspect the abdomen directly.
During laparoscopy, the surgeon may take biopsies and collect peritoneal washings for cytology. A positive finding can change the stage and prevent an unnecessary major gastrectomy that is unlikely to achieve the intended oncological result.
Whether laparoscopy is required depends on the tumour’s clinical stage, location, histology and proposed treatment. It should not be presented as mandatory for every small, early lesion.
The TNM system describes the depth of the primary tumour, regional lymph-node involvement and distant metastasis. Stage alone does not provide the complete plan, but it helps separate very early disease, resectable local or locoregional disease, unresectable disease and metastatic cancer.
Resectability means more than the technical possibility of removing the stomach. The team must consider whether the cancer can be removed completely with acceptable risk and appropriate lymph-node surgery, and whether distant or peritoneal spread makes a curative operation inappropriate.
The written plan should state the treatment intent. Curative-intent treatment aims for long-term disease control through complete local treatment combined with systemic therapy where indicated. Palliative treatment aims to control cancer, relieve symptoms, preserve function and prolong life when cure is not a realistic expectation.
Stomach cancer can cause blood loss, iron-deficiency anaemia, loss of appetite, early fullness, vomiting, weight loss and muscle loss. These problems can reduce tolerance of chemotherapy and major surgery.
Pre-treatment assessment may include a full blood count, kidney and liver tests, electrolytes, iron studies and other nutrition-related measurements. The team should review heart and lung health, diabetes, anticoagulants, previous operations, infections, mobility, functional status and the patient’s ability to eat and drink.
Nutritional support and prehabilitation should begin early when needed. Correcting dehydration, anaemia or severe malnutrition may be a necessary part of cancer treatment rather than an avoidable delay.
Biomarkers are most influential in advanced, unresectable or metastatic gastric and gastro-oesophageal junction adenocarcinoma, although MSI-H/dMMR and other selected findings may also influence perioperative discussion in resectable disease. The relevant tests depend on the stage, pathology, available tissue, previous treatment and medicines under consideration.
HER2 testing identifies tumours that may be eligible for HER2-directed treatment. It is usually assessed by immunohistochemistry, with in-situ hybridisation used in selected equivocal cases. Gastric cancer can be heterogeneous, so a small biopsy may not always represent every tumour area.
A HER2-positive result does not determine the whole regimen by itself. PD-L1 status, treatment line, previous HER2 therapy, general health, regulatory approval and medicine availability may also affect the plan.
PD-L1 may be reported using a combined positive score, or CPS, or, for certain regimens, tumour area positivity, or TAP. The assay, scoring system and threshold must match the proposed medicine and indication.
The phrase “PD-L1 positive” does not have one universal meaning. A higher score can support an immunotherapy-containing approach in certain settings, but it does not guarantee response. A low or negative result also does not answer every immunotherapy question without considering MSI/MMR, stage and the full protocol.
Microsatellite instability-high, or MSI-H, and deficient mismatch repair, or dMMR, can indicate particular sensitivity to immune-checkpoint therapy in appropriate clinical settings. Mismatch-repair findings may also raise a hereditary-risk question in selected patients.
MSI can be assessed by molecular methods, while mismatch-repair proteins can be evaluated by immunohistochemistry. The result must be interpreted together with the diagnosis, treatment setting, local approval and other clinical information.
CLDN18.2 expression can be measured by immunohistochemistry. In eligible HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, a sufficiently positive result may support consideration of CLDN18.2-directed treatment combined with chemotherapy.
Eligibility depends on the validated assay, staining definition, clinical indication and access to the medicine. A positive result does not guarantee that the treatment will be available, appropriate or effective for an individual patient.
Broader next-generation sequencing can be considered in selected advanced cases to search for uncommon actionable changes, tumour-agnostic biomarkers or clinical-trial options. It can also help clarify molecular findings after standard treatment has failed.
NGS is not required for every early stomach cancer and does not replace validated HER2, PD-L1, MSI/MMR or CLDN18.2 assays when a specific companion test is required. Tissue quality, tumour content, panel design and interpretation all affect the result. Recmed’s guide to NGS cancer testing, tissue biopsy and liquid biopsy explains these limitations in more detail.
Stomach cancer crosses several specialties. A gastroenterologist may diagnose and biopsy the lesion; a pathologist confirms its type; a radiologist and sometimes a surgeon assess the stage; a medical oncologist plans systemic treatment; an upper gastrointestinal surgeon evaluates resectability; and a dietitian helps protect nutrition before, during and after treatment.
A multidisciplinary review is especially important when:
The tumour-board conclusion should document the diagnosis, stage, resectability, treatment intent, proposed sequence, required additional tests and the specialists responsible for each step. It should also identify reasonable alternatives and explain which recommendations depend on findings that are not yet available.
Patients can review Recmed’s broader Cancer Treatment in Turkey: Patient Guide 2026 for the general international oncology pathway. The present page focuses specifically on gastric-cancer decisions.
Some cancers confined to the most superficial layers of the stomach can be removed endoscopically by an expert team. Endoscopic submucosal dissection or another endoscopic resection technique is considered only when the lesion meets strict criteria related to size, depth, ulceration, histology and estimated lymph-node risk.
The final pathology from the resected specimen determines whether the endoscopic treatment is considered adequate. If the margin, depth, lymphatic or vascular invasion, or histological features indicate a meaningful lymph-node risk, gastrectomy with lymph-node dissection may still be recommended.
When the stomach is preserved, the team may also recommend testing for and eradicating Helicobacter pylori, followed by endoscopic surveillance according to the pathology and local protocol.
For a resectable cancer that extends beyond the criteria for endoscopic treatment, surgery is generally central. The operation can be subtotal or total gastrectomy depending on tumour location and the ability to obtain an appropriate oncological margin.
Some early cancers can proceed directly to surgery, while others require a perioperative systemic-treatment discussion. The decision depends on clinical T and N stage, pathology, surgical plan, age, comorbidities, nutrition and the strength of the staging information.
For many locally advanced non-metastatic gastric or gastro-oesophageal junction adenocarcinomas, systemic treatment before and after radical surgery is considered. A commonly used perioperative chemotherapy backbone is FLOT, which combines fluorouracil, leucovorin, oxaliplatin and docetaxel.
The evidence and regulatory landscape continue to change. As of November 2026, ESMO recommends perioperative durvalumab plus FLOT, followed by durvalumab maintenance, as the preferred option for appropriate locally advanced—generally cT2 or higher or node-positive, M0—resectable gastric or gastro-oesophageal junction adenocarcinoma where the regimen is approved and available. Eligibility and access in Turkey must be confirmed individually. Fitness, immune-related risks, stage, local authorisation, hospital access and the treating team’s judgement remain essential.
If a tumour cannot be removed completely or the operative risk is unacceptable, treatment usually shifts toward systemic therapy, symptom control and reassessment. In selected situations, chemoradiotherapy or another local intervention may be considered, particularly for junctional disease, bleeding, pain or obstruction.
“Unresectable” should be explained clearly. It can reflect invasion of critical structures, extensive nodal or peritoneal disease, distant metastasis, medical frailty or a combination of these factors. A second specialist review may be useful when different teams disagree, but it cannot make an unsafe or biologically inappropriate operation beneficial.
For stage IV or recurrent disease, systemic treatment and supportive care are usually central. The first-line choice depends on HER2, PD-L1, MSI/MMR, CLDN18.2, previous treatment, organ function, symptoms and performance status.
Surgery is not a routine curative treatment for widespread metastatic stomach cancer. Selected local procedures may relieve bleeding or obstruction, and unusually limited metastatic situations may be discussed by a specialist multidisciplinary team. These exceptions should not be advertised as a standard cure.
A distal or subtotal gastrectomy removes the affected part of the stomach while preserving a portion of the organ. It may be appropriate when the tumour’s position allows an adequate margin without removing the entire stomach.
A total gastrectomy removes the whole stomach and connects the oesophagus to the small intestine. It may be required for proximal, diffuse, multifocal or extensive disease, or when a safe margin cannot otherwise be achieved.
The smallest possible operation is not always the safest oncological operation, and the largest operation is not automatically better. The surgeon must balance complete tumour removal, lymph-node surgery, reconstruction, expected function and operative risk.
Radical surgery aims to remove the tumour with clear microscopic margins together with an appropriate regional lymph-node dissection. Current European guidance recommends D2 gastrectomy at a high-volume centre for radical gastric-cancer surgery.
D2 dissection refers to removal of defined lymph-node stations around the stomach and along major vessels. It is not simply “more nodes.” The quality and safety of the procedure depend on anatomical expertise, adequate pathology assessment and experienced perioperative care.
The final pathology should report margin status, tumour depth, number of nodes examined and involved, treatment response where preoperative therapy was given, lymphovascular or perineural invasion and the pathological stage.
Gastrectomy may be performed through an open incision, laparoscopically, robotically or with a hybrid technique. Minimally invasive approaches can offer selected patients advantages such as smaller incisions and potentially faster early recovery, but the label “robotic” does not guarantee a better cancer outcome.
The choice should reflect tumour stage and location, previous abdominal surgery, body habitus, surgeon experience, the planned lymph-node dissection and the ability to manage complications. An operation should not compromise margins or nodal quality merely to use a particular technology.
After subtotal gastrectomy, the remaining stomach is connected to the small intestine or duodenum using a reconstruction selected by the surgeon. After total gastrectomy, the oesophagus is usually joined to the small intestine so that food can pass through the digestive tract.
Patients should understand how the reconstruction may affect meal size, reflux, bile flow, bowel habits, nutrient absorption and the need for long-term monitoring. The explanation should include whether temporary or longer-term feeding access might be used.
Possible early complications include bleeding, infection, pneumonia, blood clots, delayed emptying after partial gastrectomy or impaired passage through the reconstruction, bowel problems and a leak from the new surgical connection. Some complications require endoscopy, radiological drainage, another operation, intensive care or a longer admission.
Recovery varies substantially. Age, nutrition, fitness, extent of surgery, complications and whether additional treatment is planned all affect the timeline. A fixed hospital stay or flight date should not be guaranteed before surgery.
Final surgical pathology can confirm or change the stage and may affect postoperative treatment. International patients should receive the operative report, discharge summary and complete pathology report before leaving, with a plan for wound care, nutrition, medication, laboratory monitoring and urgent contact.
Perioperative treatment is systemic therapy given before and after surgery. For many fit patients with locally advanced resectable gastric or gastro-oesophageal junction adenocarcinoma, FLOT is an established chemotherapy approach. Treatment before surgery addresses microscopic disease early and can provide information about tumour response; postoperative cycles complete the planned systemic course when recovery permits.
Not every patient can tolerate a four-drug regimen. Frailty, neuropathy, kidney or liver impairment, cardiac disease, previous toxicity and poor nutrition may require a modified schedule or a different fluoropyrimidine–platinum combination. Dose changes are clinical decisions, not evidence that treatment has failed.
Before fluorouracil, capecitabine or tegafur is started, the team should verify pretreatment DPD or DPYD testing according to the applicable protocol. Complete DPD deficiency can cause life-threatening toxicity, while partial deficiency may require dose modification or an alternative treatment.
For patients with pT2 and/or node-positive disease who underwent surgery without preoperative chemotherapy, adjuvant chemotherapy may be recommended, subject to recovery, comorbidity, lymph-node-dissection quality and regional guidance. Postoperative chemoradiotherapy is selective rather than automatic after every gastrectomy.
HER2-positive advanced gastric cancer can be treated with a HER2-directed strategy combined with systemic therapy. The exact regimen depends on the intensity and confirmation of HER2 expression, PD-L1 result, previous therapy, regulatory approval and availability.
As of November 2026, ESMO recommends zanidatamab–tislelizumab–chemotherapy where available for untreated HER2-positive advanced disease. Zanidatamab–chemotherapy is also an option for HER2 IHC 3+ disease, while trastuzumab-based treatment remains relevant when newer combinations are unavailable, contraindicated or not tolerated. These recommendations do not establish Turkish marketing authorisation, stock or reimbursement.
Treatment options in this area are evolving rapidly. A report from another country may name a medicine that is not approved, stocked or reimbursed in Turkey, while a newer option may have become available after an older recommendation was written. The treating oncologist should verify the current indication rather than relying on an undated internet list.
Immune-checkpoint therapy may be combined with chemotherapy for selected advanced gastric or gastro-oesophageal junction cancers. PD-L1 scoring can help determine the strength of the indication for certain regimens. MSI-H or dMMR disease can make immunotherapy particularly relevant.
Immunotherapy can cause immune-mediated inflammation of organs such as the lungs, bowel, liver, kidneys, skin, endocrine glands, heart or nervous system. Eligibility and monitoring therefore depend on more than the tumour result. The patient’s autoimmune history, transplant history, current medicines, organ function and ability to access urgent care must be reviewed. Recmed’s immunotherapy eligibility and biomarker guide covers these issues in greater depth.
For eligible HER2-negative, CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, CLDN18.2-directed therapy combined with chemotherapy may be considered. The validated staining threshold and treatment indication must be satisfied.
Nausea and vomiting can be clinically important with some CLDN18.2-directed regimens, making antiemetic support and nutritional assessment especially relevant. A positive laboratory result alone does not replace clinical eligibility review.
If the cancer progresses, later treatment can include a taxane- or irinotecan-based approach, ramucirumab-containing therapy, HER2-directed treatment after prior HER2 therapy, or another biomarker-guided option. The choice depends on what was used previously, duration of benefit, residual side effects, organ function, symptoms and performance status.
Response is generally assessed with clinical review, blood tests and interval imaging. Tumour markers can sometimes provide supporting information but should not be used alone to declare response or progression. A new biopsy or molecular review may be useful when the disease changes and a result could affect the next decision.
Radiotherapy has a more selective role in stomach cancer than surgery and systemic therapy. It is not routinely required after every gastrectomy and should not be added merely because it is available.
Chemoradiotherapy may be considered in selected postoperative situations, particularly when the surgical margin, lymph-node assessment or other recurrence-risk factors change the balance. It may also be used for some unresectable or gastro-oesophageal junction tumours when the anatomy and treatment goals support it.
Palliative radiotherapy can help control bleeding, pain or obstruction in selected patients. Planning requires review of prior operations and chemotherapy, tumour position and the expected radiation dose to the kidneys, liver, bowel and other organs at risk.
The written recommendation should specify the purpose, planned dose and number of fractions, concurrent medicines if any, expected side effects and the criteria for interrupting or modifying treatment.
Nutrition is part of the treatment plan, not a secondary comfort issue. Stomach cancer can cause early fullness, nausea, vomiting, bleeding, anaemia, obstruction and substantial loss of weight and muscle. These problems can increase treatment toxicity and surgical risk.
The team should record recent weight change, current intake, swallowing, vomiting, bowel symptoms and physical strength. A dietitian may recommend high-protein or energy-dense foods, oral supplements, correction of deficiencies or enteral feeding when normal intake is inadequate.
Nutrition support must be individualised. Severe obstruction, aspiration risk, uncontrolled vomiting, diabetes, kidney disease and treatment side effects can change what is safe.
After gastrectomy, patients often tolerate smaller and more frequent meals better than three large meals. Eating slowly, chewing carefully and adjusting the amount and timing of fluids may help, but advice should be personalised to the reconstruction and symptoms.
Loss of appetite and weight is common during recovery. The goal is to maintain hydration, protein and energy intake while the digestive system adapts. A dietitian should review persistent weight loss, diarrhoea, reflux, nausea, food sticking or inability to meet nutritional needs.
Dumping syndrome occurs when food, especially a high-sugar meal, passes rapidly into the small intestine. Symptoms can include abdominal cramping, diarrhoea, palpitations, sweating, dizziness or weakness soon after eating; later low blood glucose can occur in some patients.
Long-term monitoring may include vitamin B12, iron, folate, calcium, vitamin D and other measurements according to the operation and symptoms. Total gastrectomy usually creates an ongoing need for vitamin B12 replacement. The exact route and schedule should be prescribed by the treating team.
Temporary tube feeding or another form of nutrition support may be used when the patient cannot meet requirements safely by mouth. The route depends on the tumour, operation, bowel function, expected duration and aspiration risk.
Parenteral nutrition is reserved for selected situations in which the digestive tract cannot be used adequately. It carries infection and metabolic risks and should be supervised by an experienced clinical team.
Advanced stomach cancer can cause vomiting blood, black stools, anaemia, pain, obstruction, ascites, nausea and inability to maintain nutrition. Symptom control should begin alongside anticancer treatment rather than waiting until all tumour-directed options are exhausted.
The appropriate intervention depends on the immediate problem and overall treatment goals. Blood transfusion, iron replacement, antiemetics, analgesia, acid suppression, drainage of ascites and nutrition support may be required.
An endoscopic stent can sometimes keep a narrowed passage open. A surgical bypass may be considered when obstruction cannot be managed endoscopically and the patient is fit enough. Radiotherapy or another local procedure may help control bleeding or pain.
Cytoreductive surgery and heated intraperitoneal chemotherapy, often called HIPEC, should not be presented as routine treatment for gastric-cancer peritoneal metastases. These approaches are highly selected and may be considered only in specialised programmes or clinical trials after careful multidisciplinary review.
Early palliative-care involvement can improve symptom control, communication and support for patients and families while active cancer treatment continues. It does not mean that other treatment has stopped.
Patients should seek urgent medical care where they are for:
Do not wait for an international appointment, online reply or flight when emergency assessment is needed.
A second opinion may be useful before a major or irreversible step, particularly when:
A second opinion does not always produce a different plan. Confirmation that the initial recommendation is appropriate can still be valuable before complex surgery or prolonged treatment.
The review is only as reliable as the records provided. If pathology material, original imaging or key staging information is missing, the opinion should be described as preliminary.
The initial file should usually include:
Use clear filenames containing the document type and date, such as “2026-10-04 CT chest-abdomen-pelvis report.” Arrange records chronologically and keep pathology, imaging, treatment and laboratory folders separate.
Do not replace DICOM studies with screenshots or photographs of films. If the file transfer is large, use the secure method agreed with the reviewing team. Pathology blocks and slides should be transported only after confirming the receiving laboratory’s requirements, customs documentation and return arrangements.
If records are not in English or Turkish, ask whether a certified or medical translation is needed. Do not alter medicine names, doses, dates or measurements during translation.
Often, a preliminary specialist opinion can be prepared from complete records before travel. This can help determine whether the case is likely to require endoscopy, pathology review, new imaging, staging laparoscopy, surgery, systemic treatment or another specialist assessment.
Remote review can also reveal that urgent local care is needed or that the proposed treatment is available closer to home. It can reduce unnecessary travel when the patient is medically unstable or the records do not yet support a meaningful recommendation.
A remote opinion cannot always confirm resectability, anaesthetic fitness, nutritional status or the exact operation. The final plan may change after physical examination, direct review of imaging, repeat biopsy, laparoscopy or multidisciplinary discussion in Turkey.
The first step is to identify what information exists and what is missing. The coordinator should not promise an operation or medicine before the clinical team has confirmed pathology, stage and treatment intent.
The main reviewing specialist may be an upper gastrointestinal surgeon, medical oncologist or gastroenterologist, depending on the immediate question. Complex cases may require more than one specialist from Recmed’s doctor directory.
The team reviews pathology, imaging, treatment history, biomarker information, nutrition and medical fitness. The result should state whether the records support a recommendation and which decisions require further testing.
The proposal should explain the proposed sequence, clinical purpose, expected investigations, likely hospital stay, important risks, follow-up needs and alternatives. The estimate should separate confirmed items from costs that depend on new findings.
Flights, accommodation and visas should be arranged only after the medical team has accepted the case and estimated the first phase of care. Patients with active bleeding, severe vomiting, dehydration, infection, recent major surgery or thromboembolic risk may need medical stabilisation or formal fitness-to-fly assessment.
Before leaving Turkey, the patient should receive the discharge summary, operative and pathology reports, medication list, treatment protocol, laboratory and imaging results, nutrition instructions, follow-up schedule and a clear plan for urgent problems.
This guidance is also relevant to patients and families travelling from Nigeria, Ghana, Kenya, Uganda, Tanzania, South Africa, Zambia, Zimbabwe, Sierra Leone, Liberia, The Gambia, Botswana, Namibia, Rwanda and other countries where English is commonly used for healthcare communication. These countries should not be treated as one medical or administrative category. Passport rules, flight routes, insurance, local treatment access and follow-up arrangements differ by country and by patient.
Before booking flights, confirm:
Visa rules can change and depend on nationality and passport type. Patients should check the Republic of Türkiye Ministry of Foreign Affairs, the official e-Visa portal or the responsible Turkish diplomatic mission. A hospital or coordinator letter may support an application but cannot guarantee a visa or entry.
Bring essential medicines in their original labelled packaging together with prescriptions and a doctor’s letter that lists generic names, doses, allergies and diagnoses. Keep important medicines in carry-on luggage where permitted and bring enough for the planned stay plus a reasonable delay. Do not stop anticoagulants, diabetes medicines, steroids or anticancer treatment without instructions from the responsible clinical team.
A travelling companion may be especially helpful after gastrectomy or during intensive treatment. The travel plan should account for mobility, wound care, nutrition, baggage restrictions for medical supplies and access to emergency care during transit.
There is no single responsible price for stomach cancer treatment. Two patients with the same headline diagnosis can require very different staging, operations, medicines, hospital stays and follow-up.
Cost can be affected by:
After reviewing the records, the patient should request an itemised written estimate. It should distinguish the price of one treatment cycle from the projected full course, medical charges from travel services, included hospital nights from extra days and confirmed services from possible additional tests.
A low headline price can be misleading if it excludes medicines, pathology, anaesthesia, lymph-node surgery, intensive care, complication management or follow-up. Comparisons should use the same clinical scope. Insurance, employer or public-authority reimbursement must be confirmed in writing with the relevant payer; it should not be promised by a medical-travel coordinator.
The required stay depends on the purpose of travel. A consultation and records review may be completed within a short visit. Endoscopy, repeat biopsy or staging laparoscopy requires time for preparation, procedure and pathology. Gastrectomy requires admission, recovery and assessment of fitness to travel. Radiotherapy or complications may require a longer stay.
Patients receiving perioperative chemotherapy may not need to remain in Turkey for every cycle if an appropriate home-country oncology team can follow the same protocol safely. This must be agreed before treatment begins, including laboratory monitoring, dose-modification rules and responsibility for urgent toxicity.
A return ticket should not be treated as a medical discharge date. Flight timing after surgery depends on recovery, nutrition, wound status, blood-clot risk, complications and the surgeon’s assessment.
Continuity should be planned before the patient travels. A local oncologist, surgeon or primary doctor should be identified whenever possible, especially if chemotherapy, wound care, vitamin replacement or nutritional monitoring will continue after return.
The handover package should include:
Follow-up is individualised according to stage, treatment and symptoms. It can include clinical visits, laboratory tests, nutrition review, endoscopy and CT or other imaging. Advanced disease under systemic treatment usually requires periodic response assessment.
Teleconsultation can support continuity but cannot replace local emergency care. New bleeding, persistent vomiting, fever, severe pain, dehydration, breathlessness or sudden deterioration requires assessment where the patient is located.
Before accepting a proposal, ask whether it clearly states:
A proposal that guarantees operability, promises a cure, names a drug without confirming the biomarker indication or gives a fixed price without reviewing the records should be treated cautiously.
Recmed Medical Travel coordinates international-patient services; it does not diagnose disease or prescribe treatment. Depending on the case, coordination may include:
Diagnosis, resectability, treatment eligibility and all clinical decisions remain the responsibility of licensed physicians and medical institutions. Recmed cannot guarantee a particular operation, medicine, visa decision or treatment result.
No. Selected very early superficial cancers may be removed endoscopically. Many localised cancers require gastrectomy, while unresectable or metastatic disease is usually treated primarily with systemic therapy and symptom control. The decision depends on pathology, stage, resectability and patient fitness.
Yes, in carefully selected lesions with a very low estimated risk of lymph-node spread. The final resection pathology must confirm whether the endoscopic treatment is adequate. If the depth, margin or biological features are unfavourable, surgery may still be recommended.
Partial or subtotal gastrectomy removes the affected portion of the stomach and preserves the remainder. Total gastrectomy removes the entire stomach and connects the oesophagus to the small intestine. Tumour location, extent and required margins determine which operation is oncologically appropriate.
D2 dissection removes defined regional lymph-node stations around the stomach and major vessels as part of radical gastric-cancer surgery. It helps stage the cancer and control regional disease. It should be performed by a team experienced in gastric surgery rather than described simply as removal of “many nodes.”
No. Perioperative chemotherapy is commonly considered for locally advanced resectable disease, but selected early cancers can proceed directly to local treatment. Frailty, organ function, stage, pathology and postoperative recovery can modify the plan.
These tests are particularly important when advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma is being treated systemically. The complete panel may not be necessary for every very early cancer. The oncologist and pathologist should decide which results could change the current treatment decision.
No. Broader NGS can be useful in selected advanced cases, uncommon presentations or when standard options are limited. It does not replace required single-marker or immunohistochemical tests, and it may not alter treatment when the disease is early and managed with established local and perioperative strategies.
No. A biomarker can support eligibility or increase the expected likelihood of benefit in a defined clinical setting, but it cannot guarantee response. Stage, treatment line, assay, threshold, previous therapy, overall health and medicine availability also matter.
Not as routine curative treatment. Local procedures can sometimes relieve bleeding or obstruction, and a very limited metastatic situation may be reviewed individually. Widespread metastatic disease is generally managed with systemic therapy and supportive care.
No. Cytoreductive surgery and HIPEC are not routine treatment for most gastric-cancer peritoneal metastases. They may be investigated or used in highly selected specialist programmes. Patients should ask about evidence, selection criteria, risks and alternatives.
Sometimes urgent symptoms require treatment before every result is complete. In other situations, waiting for a clinically relevant result can prevent the wrong first-line strategy. The oncologist must decide whether waiting is medically safe.
It may be enough for an initial review, but not always for a definitive conclusion. Original slides or paraffin blocks may be needed when the diagnosis is uncertain, the tumour is unusual or biomarker testing requires more tissue.
Yes, whenever available. DICOM files allow the reviewing radiologist and treatment team to inspect the complete study. A written report, phone photograph or screenshot cannot replace direct image review.
Often, yes. A preliminary review can identify the likely pathway and missing information. A final decision may still require examination, updated imaging, pathology review, endoscopy, diagnostic laparoscopy or another biopsy in Turkey.
It may be possible if the medicines, monitoring and oncology expertise are available. The Turkish and home-country teams should agree on the exact protocol, laboratory schedule, dose-modification rules, imaging plan and emergency responsibilities.
Urgent assessment is needed for vomiting blood, black stools, severe abdominal pain, persistent vomiting, inability to keep liquids down, fever during treatment, wound infection, new breathlessness or chest pain, fainting, confusion, marked dehydration or sudden deterioration. Seek local emergency care rather than waiting to travel.
If you are considering stomach cancer treatment in Turkey, begin by sending the available endoscopy, pathology, imaging, treatment and biomarker records together with recent blood tests and a concise description of current symptoms, weight loss and ability to eat.
The initial purpose is to determine whether the documentation is sufficiently complete, which licensed specialist is most appropriate and whether additional information is needed before travel is considered. Records should be transferred through a confirmed secure channel and with the patient’s consent.
A records check does not confirm the diagnosis, guarantee treatment acceptance or promise that surgery or a particular medicine will be suitable. The responsible medical team must determine whether remote review is sufficient and whether the patient is medically fit to travel.
Request a Stomach Cancer Case Review
This article provides general information and is not medical advice, a diagnosis or an individual treatment recommendation. The appropriate pathology review, staging tests, biomarker studies, operation, systemic-treatment sequence, nutrition plan and assessment of fitness to travel must be determined by licensed clinicians who have reviewed the patient’s complete medical information.
Do not start, stop, delay or change cancer treatment on the basis of this article. Patients with urgent or rapidly worsening symptoms should seek immediate medical care where they are rather than waiting for an international consultation or travel.
Recmed Medical Travel coordinates international medical services. It does not diagnose disease, prescribe treatment, determine treatment eligibility or guarantee results.